Watkins Says Benlysta Could Be Available by End of 2010: Video

Nov. 2 (Bloomberg) -- Thomas Watkins, chief executive officer of Human Genome Sciences Inc., talk...  More »

Nov. 2 (Bloomberg) -- Thomas Watkins, chief executive officer of Human Genome Sciences Inc., talks with Bloomberg's Carol Massar and Matt Miller about the outlook for U.S. regulators' approval of the company's experimental lupus drug Benlysta. Human Genome, based in Rockville, Maryland, said Benlysta worked in a higher dose to reduce symptoms in a study. The company also said it will seek permission to sell the drug, marketed with London-based GlaxoSmithKline Plc, in the first half of next year. (Source: Bloomberg)  « Less